Home › Wilms Tumor
Wilms Tumor clinical trials recruiting in the U.S.
17 studies for Wilms Tumor are recruiting participants at sites across the United States.
Wilms' Tumor (or Nephroblastoma) is a rare type of cancer that affects one or both kidneys. Find a list of symptoms and treatments associated
Cities with the most studies
- Washington, DC7 studies
- Memphis, TN6 studies
- Atlanta, GA5 studies
- Minneapolis, MN4 studies
- Houston, TX4 studies
- Greenburgh, NY4 studies
- Los Angeles, CA4 studies
- New York City, NY4 studies
- Philadelphia, PA4 studies
- Boston, MA4 studies
- Mountain View, CA4 studies
- Aurora, CO4 studies
- Cincinnati, OH4 studies
- Chicago, IL4 studies
- St. Louis, MO4 studies
- Ann Arbor, MI3 studies
- Birmingham, AL3 studies
By state
- Alabama3 studies
- California5 studies
- Colorado4 studies
- District of Columbia7 studies
- Florida3 studies
- Georgia5 studies
- Illinois4 studies
- Massachusetts4 studies
- Michigan3 studies
- Minnesota5 studies
- Missouri4 studies
- New York6 studies
- Ohio5 studies
- Pennsylvania4 studies
- Tennessee6 studies
- Texas6 studies
Recently updated studies
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 29, 2026 · NCT04616560Biomarkers of Resiliency In Childhood Cancer Surgery
RecruitingObservational study
Ages 3 to 25 · All sexes · Updated Sep 14, 2026 · NCT06674811A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
RecruitingPhase 2
Up to age 30 · All sexes · Updated Aug 25, 2026 · NCT04322318Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RecruitingPhase 1
Ages 1 to 23 · All sexes · Updated Aug 13, 2026 · NCT07172958Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Aug 6, 2026 · NCT04715191Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Jun 30, 2026 · NCT06625190Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RecruitingPhase 2
12 Months · All sexes · Updated May 6, 2026 · NCT05985161Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
RecruitingPhase 2
All ages · All sexes · Updated Apr 23, 2026 · NCT04968990Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Apr 15, 2026 · NCT04308330Pencil Beam Scanning in Patients With Renal Tumors
RecruitingEarly phase 1
Ages 0 to 30 · All sexes · Updated Apr 15, 2026 · NCT03810651Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Feb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RecruitingPhase 1
Up to age 21 · All sexes · Updated Nov 3, 2025 · NCT06198296A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RecruitingPhase 2
18 Months – 40 Years · All sexes · Updated Aug 12, 2025 · NCT05135975International PPB/DICER1 Registry
RecruitingObservational studyHealthy volunteers welcome
0 Minutes – 100 Years · All sexes · Updated Jan 30, 2025 · NCT03382158From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.